Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1230-1236

  Geisler, Ju¨rgen ^a   Detre, Simone ^c   Berntsen, Hildegunn ^a   Ottestad, Lars ^d   Lindtjørn, Bernt ^b   Dowsett, Mitch ^c   Lønning, Per Eystein ^a  

^a Departments of Oncology   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; ESTRONE SULFATE;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; DRUG EFFECT; ESTROGEN RELEASE; ESTROGEN SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; NORWAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; TISSUE LEVEL; TUMOR BIOPSY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; ESTROGENS; FEMALE; HORMONES; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; NITRILES; POSTMENOPAUSE; PROTEINS; RECEPTORS, GROWTH FACTOR; TRIAZOLES; TUMOR SUPPRESSOR PROTEINS;

EID: 0034901971     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two Phase III trials
2. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared to megestrole acetate
3. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer
4. Influence of anastrozole (Arimidex), a selective, nonsteroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
5. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
6. In situ estrogen production via the estrone sulfatase pathway in breast tumors: Relative importance versus the aromatase pathway
7. The relationship between 17-β-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue
8. Breast cancer and the role of cytokines in regulating estrogen synthesis: An emerging hypothesis
9. Mechanism of maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: Role of very high affinity tissue uptake
10. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol, and estrone sulphate levels in breast cancer tissue
11. Differential influence of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients
12. Plasma levels of estradiol, estrone, estrone sulfate, and sex hormone binding globulin in patients receiving rifampicin
13. Assessment of response to therapy in advanced breast cancer
14. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route
15. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I, and insulin-like growth factor binding protein-I in post-menopausal breast cancer patients
16. A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors
17. Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay
18. Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts
19. Reduced apoptosis and proliferation and increased bcl-2 in residual breast cancer following preoperative chemotherapy
20. Expression of epidermal growth factor receptor and c-erbB-2 during the development of tamoxifen resistance in human breast cancer
21. Estrone and estradiol content in human breast tumors: Relationship to estradiol receptors
22. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients
23. Aromatase, 17-β-hydroxysteroid dehydrogenase and intratissue sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women
24. Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue
25. Importance of intratumour aromatase and its susceptibility to inhibitors
26. Oestrogen uptake and metabolism in vivo
27. Control of aromatase activity in breast cancer cells: The role of cytokines and growth factors
28. Regulation of aromatase expression in human tissues
29. Concentration of endogenous oestradiol as related to oestradiol receptor sites in breast tumor cytosol
30. Endogenous C19-steroids and oestradiol levels in human primary breast tumour tissues and their correlation with androgen and oestrogen receptors
31. Endogenous oestradiol-17-β concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: Relationship to receptor content
32. Testosterone, dihydrotestosterone, and oestradiol levels in postmenopausal breast cancer tissues
33. Determination of hormonal steroid concentrations in biological extracts by high resolution mass fragmentography
34. Oestradiol levels in fractions of human breast tumours
35. Steroid-hormongehalt der brustsubstanz bei mammatumoren
36. Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissue
37. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole
38. Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast
39. Estrone sulfate: A potential source of estradiol in human breast cancer tissue
40. Predicting response to endocrine therapy in human breast cancer: A hypothesis
41. Cloning of cDNA sequences of hormone-regulated genes from MCF-7 human breast cancer cell line
42. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
43. Mutations in exons 5-8 of the p53 gene, independent of their type and localisation, are associated with increased apoptosis and mitosis in invasive breast carcinoma
44. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer
45. A randomised multicentre study of vorozole compared to tamoxifen as primary therapy in post-menopausal breast cancer